Such data advance our understanding of S100A1’s molecular function and, most likely, differentiate for the first time between diastolic redox-sensitive and systolic redox-insensitive molecular mechanisms that are expected to be of equal relevance for S100A1’s therapeutic efficacy in human heart failure. Here, S100A1 is linked to heart failure.